Is Incyte (INCY) overvalued or fairly valued?

MarketChacha shows Incyte's valuation in context — a forward P/E of about 13.3, a price-to-book of about 4.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is the share price of Incyte (INCY)?

Incyte last traded at $116.78 (-0.5% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Incyte

INCY · NASDAQ · Healthcare · United States

$116.78-0.5%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 5:37 PM

Snapshot

TickerINCY

ExchangeNASDAQ

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees2,844

HeadquartersWilmington, United States

Market cap$23.3B

P/B4.2

Volume361.07K

Websitewww.incyte.com

Filings tracked0

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Profile as reported by Yahoo Finance.

Who owns it

Insiders1.9%
Institutions98.1%
Public & other0.0%

1,242 institutional holders

As reported by Yahoo Finance.

Top holders

Baker Bros. Advisors, LP15.39%
Blackrock Inc.9.50%
Dodge & Cox Inc.6.13%
Vanguard Capital Management LLC5.47%
State Street Corporation4.83%
Vanguard Portfolio Management LLC3.88%
AQR Capital Management, LLC2.91%
Geode Capital Management, LLC2.35%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

What's expected next

Next quarter

Rev $1.5B · EPS -3.45

Est. earnings growth -252.5%

Next fiscal year

Rev $6.2B · EPS 8.78

Est. earnings growth +212.1%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$69.2452-wk range$119.60

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Ask MarketChacha about INCY

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.